News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
543,451 Results
Type
Article (33552)
Company Profile (87)
Press Release (509810)
Multimedia
Podcasts (47)
Webinars (9)
Section
Business (151099)
Career Advice (833)
Deals (25683)
Drug Delivery (65)
Drug Development (69460)
Employer Resources (69)
FDA (14342)
Job Trends (11115)
News (264429)
Policy (24882)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1974)
Accelerated approval (21)
Adcomms (16)
Allergies (134)
Alliances (35422)
ALS (127)
Alzheimer's disease (1309)
Antibody-drug conjugate (ADC) (220)
Approvals (14683)
Artificial intelligence (372)
Autoimmune disease (132)
Automation (15)
Bankruptcy (221)
Best Places to Work (8858)
BIOSECURE Act (5)
Biosimilars (114)
Biotechnology (64)
Bladder cancer (140)
Brain cancer (47)
Breast cancer (533)
Cancer (3987)
Cardiovascular disease (359)
Career advice (735)
Career pathing (18)
CAR-T (225)
CDC (36)
Celiac Disease (2)
Cell therapy (558)
Cervical cancer (33)
Clinical research (61041)
Collaboration (1141)
Compensation (607)
Complete response letters (41)
COVID-19 (2359)
CRISPR (58)
C-suite (679)
Cystic fibrosis (108)
Data (5535)
Decentralized trials (2)
Denatured (22)
Depression (127)
Diabetes (421)
Diagnostics (4851)
Digital health (34)
Diversity (8)
Diversity, equity & inclusion (23)
Drug discovery (141)
Drug pricing (108)
Drug shortages (28)
Duchenne muscular dystrophy (181)
Earnings (64766)
Editorial (32)
Employer branding (11)
Employer resources (71)
Events (82442)
Executive appointments (802)
FDA (17106)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (18)
Funding (1072)
Gene editing (131)
Generative AI (29)
Gene therapy (450)
GLP-1 (843)
Government (3685)
Grass and pollen (5)
Guidances (320)
Healthcare (15276)
HIV (50)
Huntington's disease (37)
IgA nephropathy (73)
Immunology and inflammation (164)
Immuno-oncology (39)
Indications (96)
Infectious disease (2575)
Inflammatory bowel disease (158)
Inflation Reduction Act (9)
Influenza (84)
Intellectual property (165)
Interviews (88)
IPO (11983)
IRA (25)
Job creations (2572)
Job search strategy (669)
JPM (29)
Kidney cancer (15)
Labor market (41)
Layoffs (309)
Leadership (14)
Legal (5148)
Liver cancer (79)
Longevity (10)
Lung cancer (580)
Lymphoma (331)
Machine learning (19)
Management (23)
Manufacturing (453)
MASH (148)
Medical device (13760)
Medtech (13807)
Mergers & acquisitions (14480)
Metabolic disorders (1092)
Multiple sclerosis (130)
NASH (17)
Neurodegenerative disease (242)
Neuropsychiatric disorders (69)
Neuroscience (2300)
NextGen: Class of 2026 (4901)
Non-profit (3305)
Now hiring (39)
Obesity (516)
Opinion (148)
Ovarian cancer (146)
Pain (186)
Pancreatic cancer (183)
Parkinson's disease (232)
Partnered (24)
Patents (309)
Patient recruitment (483)
Peanut (50)
People (47647)
Pharmaceutical (21)
Pharmacy benefit managers (17)
Phase 1 (19754)
Phase 2 (26656)
Phase 3 (19753)
Pipeline (4513)
Policy (147)
Postmarket research (2173)
Preclinical (6484)
Press Release (68)
Prostate cancer (213)
Psychedelics (36)
Radiopharmaceuticals (232)
Rare diseases (671)
Real estate (4059)
Recruiting (26)
Regulatory (19752)
Reports (25)
Research institute (1883)
Resumes & cover letters (108)
Rett syndrome (26)
RNA editing (8)
RSV (59)
Schizophrenia (140)
Series A (172)
Series B (147)
Service/supplier (2)
Sickle cell disease (71)
Special edition (7)
Spinal muscular atrophy (145)
Sponsored (23)
Startups (2639)
Stomach cancer (13)
Supply chain (80)
Tariffs (35)
The Weekly (25)
Vaccines (848)
Venture capital (39)
Weight loss (345)
Women's health (62)
Worklife (4)
Date
Today (123)
Last 7 days (445)
Last 30 days (1569)
Last 365 days (23193)
2026 (2502)
2025 (23424)
2024 (27616)
2023 (31781)
2022 (41580)
2021 (44760)
2020 (42867)
2019 (36097)
2018 (27591)
2017 (25298)
2016 (24006)
2015 (28684)
2014 (22171)
2013 (18375)
2012 (19727)
2011 (20339)
2010 (19279)
Location
Africa (535)
Alabama (51)
Alaska (4)
Arizona (205)
Arkansas (10)
Asia (32384)
Australia (5256)
California (8409)
Canada (2531)
China (939)
Colorado (356)
Connecticut (364)
Delaware (297)
Europe (67925)
Florida (1335)
Georgia (284)
Hawaii (1)
Idaho (47)
Illinois (704)
India (48)
Indiana (440)
Iowa (14)
Japan (391)
Kansas (111)
Kentucky (33)
Louisiana (21)
Maine (77)
Maryland (1121)
Massachusetts (6027)
Michigan (214)
Minnesota (548)
Mississippi (5)
Missouri (100)
Montana (29)
Nebraska (25)
Nevada (96)
New Hampshire (74)
New Jersey (2528)
New Mexico (15)
New York (2266)
North Carolina (1151)
North Dakota (9)
Northern California (4144)
Ohio (262)
Oklahoma (14)
Oregon (34)
Pennsylvania (1783)
Puerto Rico (20)
Rhode Island (38)
South America (745)
South Carolina (63)
Southern California (3244)
Tennessee (146)
Texas (1384)
United States (30843)
Utah (281)
Virginia (213)
Washington D.C. (61)
Washington State (614)
West Virginia (4)
Wisconsin (100)
Wyoming (1)
543,451 Results for "dose medical corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
January 12, 2026
·
9 min read
Press Releases
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
Pathologic Clearance: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Pathologic Results Assessed at Approximately 5 Weeks Safety Monitoring Committee Issues Favorable Review of Safety Data at the Maximum Dose
November 3, 2025
·
5 min read
Earnings
Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight loss even at monthly or longer schedules.
February 4, 2026
·
2 min read
·
Tristan Manalac
Gene therapy
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
The gene therapy uses an AAV vector to restore healthy levels of the alpha-galactosidase enzyme, which is rendered dysfunctional in patients with Fabry disease, leading to the toxic build-up of lipids in cells.
February 9, 2026
·
1 min read
·
Tristan Manalac
Press Releases
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
January 29, 2026
·
6 min read
Press Releases
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
February 2, 2026
·
2 min read
Press Releases
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial
January 12, 2026
·
9 min read
Press Releases
SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy
February 9, 2026
·
5 min read
Press Releases
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
February 12, 2026
·
6 min read
Press Releases
Ensem Therapeutics Doses First Patient in China in ETX-636 Global Phase 1/2 Study
February 2, 2026
·
4 min read
1 of 54,346
Next